Cascadian Therapeutics (Cascadian Therapeutics) Total Stockholders Equity : $109.04 Mil (As of Dec. 2017)

View and export this data going back to 1991. Start your Free Trial

What is Cascadian Therapeutics Total Stockholders Equity?

Cascadian Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2017 was $109.04 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Cascadian Therapeutics's Book Value per Share for the quarter that ended in Dec. 2017 was $2.15. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Cascadian Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2017 was 0.00.

Cascadian Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Cascadian Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Total Stockholders Equity Chart

Cascadian Therapeutics Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Stockholders Equity

Get a 7-Day Free Trial

71.55

91.27

83.74

74.36

109.04

Cascadian Therapeutics Quarterly Data
	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
Total Stockholders Equity	Get a 7-Day Free Trial															74.36	151.69	137.91	124.62	109.04

Cascadian Therapeutics (NAS:CASC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Cascadian Therapeutics's Book Value per Share for the quarter that ended in Dec. 2017 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(109.036	-	0)	/	50.5986
	=	2.15

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Cascadian Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2017 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	109.036
	=	0.00

Cascadian Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cascadian Therapeutics (Cascadian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (NAS:CASC) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cascadianrx.com

Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Executives

Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Gwen A. Fyfe	director	C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Steven P James	director	C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Julia Marie Eastland	officer: CFO & CBO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Robert Azelby	director	307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Scott Dunseth Myers	director, officer: President and CEO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 15 Gp, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Jon Sakoda	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025

Cascadian Therapeutics (Cascadian Therapeutics) Headlines

From GuruFocus

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics

By Kyle Ferguson Kyle Ferguson • 07-11-2016

Value Betting with Special Situations: Lessons from the World of Gambling

By Henniker82 Henniker82 • 03-05-2013

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines

By Holly LaFon Holly LaFon • 07-12-2016